Colchicine for reduction of Atrial Fibrillation after coronary artery bypass - randomized study

Hospital Santa Casa de Misericórdia de Curitiba0 个研究点开始时间: 2015年5月22日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Patients were recruited willing and able to provide informed consent and in accordance with the study procedures. All aged greater than or equal to 18 years; indication for elective coronary artery bypass grafting; sinus rhythm on the day preceding surgery. The mean age was 60.3 ± 8.1 years in the control group and 61.5 ± 10.3 years in the colchicine group (p = 0.44), 45 participants were female and 95 male. The sample size was 140 patients

•Exclusion criteria were: contraindication for use of study medication; atrial fibrillation or atrial flutter previously diagnosed; need for associated valve surgery; severe liver disease (transaminases above 1.5 times normal); renal failure (creatinine> 2 mg / dl); gastrointestinal diseases known; current treatment with colchicine; cardiogenic shock; severe arrhythmias; neoplasms; patients not communicative; Simultaneous use of antiarrhythmic drugs, excluding digoxin, beta-blockers and calcium channel blockers.

发起方

Hospital Santa Casa de Misericórdia de Curitiba